ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targetin... ( TORONTO Jan. 31 / ARIUS Research ...)

ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody

Date:1/31/2008

TORONTO, Jan. 31 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that it has entered into a cGMP contract manufacturing agreement for its Trop-2 Signal Transduction Antibody Program with Laureate Pharma, a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. ARIUS' Trop-2 antibody program targets a novel marker that has been linked in the scientific literature to aggressive cancers including pancreatic, colon, breast and prostate cancer.

"The initiation of manufacturing for our second drug candidate demonstrates our ability to execute on our milestones and move multiple candidates from the ARIUS pipeline of drug candidates forward," said Dr. David S. Young, President and Chief Executive Officer of ARIUS. "Laureate Pharma has a track record of expertise in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials and will provide us with a supply of our Trop-2 targeting drug necessary to begin our preclinical studies in the first quarter of 2008 in preparation for human clinical trials."

"Our specialized experience in the manufacture of monoclonal antibodies makes us an ideal partner to support ARIUS and the manufacturing of their Trop-2 Signal Transduction Antibody," said Robert J. Broeze, Ph.D., President & CEO of Laureate. "As with all of our Life Science client companies, we will work closely with the ARIUS team to help them achieve their manufacturing objectives."

ARIUS' Trop-2 Signal Transduction Antibody Program has produced the only unconjugated antibody currently in development targeting this novel marker. Trop-2 is a protein expressed on the cell-surface and found in many cancer indications including pancreatic, colon, breast and prostate cancer. The target is thought to be a key part of the expansive MAPK pathway.
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
2. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
3. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
4. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
5. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
8. ARIUS to present at Chinese Global Financial Forum
9. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
10. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
11. Arius Features Preclinical Data on Antibody Candidates at Two Conferences

Post Your Comments:

ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targetin...( TORONTO Jan. 31 / ARIUS Research ...)